Since, IPA-3 selectively inhibits PAK1 and does not cause inhibition of groups II PAKs (including PAK4), these results suggest that while targeting PAK4 in anaplastic thyroid cancer cells is a viable option, targeting PAK1 is not. Here, PAK4 is linked to thyroid gland undifferentiated (anaplastic) carcinoma.